Compare CSBR & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CSBR | IXHL |
|---|---|---|
| Founded | 1985 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.7M | 97.6M |
| IPO Year | 2015 | 2024 |
| Metric | CSBR | IXHL |
|---|---|---|
| Price | $6.34 | $3.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.7K | ★ 3.6M |
| Earning Date | 06-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $2,900,000.00 | $12,000.00 |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $0.11 |
| 52 Week High | $10.25 | $6.39 |
| Indicator | CSBR | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 56.76 |
| Support Level | $6.11 | $0.31 |
| Resistance Level | $6.24 | $5.17 |
| Average True Range (ATR) | 0.21 | 0.54 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 78.75 | 50.60 |
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.